Product References
Canagliflozin alleviates high glucose-induced peritoneal fibrosis via HIF-1α inhibition.
Frontiers in pharmacology
Wang J,Lv X,A-Ni-Wan AS,Tian SS,Wang JM,Liu HY,Fan XG,Zhou SJ,Yu P
Wed May 31 00:00:00 UTC 2023
Sodium Glucose Cotransporter-2 Inhibitor Empagliflozin Reduces Infarct Size Independently of Sodium Glucose Cotransporter-2.
Circulation
Chen S,Wang Q,Christodoulou A,Mylonas N,Bakker D,Nederlof R,Hollmann MW,Weber NC,Coronel R,Wakker V,Christoffels VM,Andreadou I,Zuurbier CJ
Tue Jan 17 00:00:00 UTC 2023
Canagliflozin Inhibits Glioblastoma Growth and Proliferation by Activating AMPK.
Cellular and molecular neurobiology
Shoda K,Tsuji S,Nakamura S,Egashira Y,Enomoto Y,Nakayama N,Shimazawa M,Iwama T,Hara H
Wed Mar 01 00:00:00 UTC 2023
Canagliflozin Inhibits Glioblastoma Growth and Proliferation by Activating AMPK.
Cellular and molecular neurobiology
Shoda K,Tsuji S,Nakamura S,Egashira Y,Enomoto Y,Nakayama N,Shimazawa M,Iwama T,Hara H
Wed Mar 01 00:00:00 UTC 2023
Canagliflozin Inhibits Glioblastoma Growth and Proliferation by Activating AMPK.
Cellular and molecular neurobiology
Shoda K,Tsuji S,Nakamura S,Egashira Y,Enomoto Y,Nakayama N,Shimazawa M,Iwama T,Hara H
Wed Mar 01 00:00:00 UTC 2023
Canagliflozin Inhibits Glioblastoma Growth and Proliferation by Activating AMPK.
Cellular and molecular neurobiology
Shoda K,Tsuji S,Nakamura S,Egashira Y,Enomoto Y,Nakayama N,Shimazawa M,Iwama T,Hara H
Wed Mar 01 00:00:00 UTC 2023
PCK1 is a key regulator of metabolic and mitochondrial functions in renal tubular cells.
American journal of physiology. Renal physiology
Verissimo T,Dalga D,Arnoux G,Sakhi I,Faivre A,Auwerx H,Bourgeois S,Paolucci D,Gex Q,Rutkowski JM,Legouis D,Wagner CA,Hall AM,de Seigneux S
Thu Jun 01 00:00:00 UTC 2023
Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling.
The Journal of clinical investigation
Ding L,Chen X,Zhang W,Dai X,Guo H,Pan X,Xu Y,Feng J,Yuan M,Gao X,Wang J,Xu X,Li S,Wu H,Cao J,He Q,Yang B
Tue Jan 03 00:00:00 UTC 2023
Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling.
The Journal of clinical investigation
Ding L,Chen X,Zhang W,Dai X,Guo H,Pan X,Xu Y,Feng J,Yuan M,Gao X,Wang J,Xu X,Li S,Wu H,Cao J,He Q,Yang B
Tue Jan 03 00:00:00 UTC 2023
USP22-mediated deubiquitination of PTEN inhibits pancreatic cancer progression by inducing p21 expression.
Molecular oncology
Ren D,Sun Y,Li D,Wu H,Jin X
Tue Mar 01 00:00:00 UTC 2022
Sodium-glucose cotransporter-2 (SGLT2) expression in diabetic and non-diabetic failing human cardiomyocytes.
Pharmacological research
Marfella R,Scisciola L,D'Onofrio N,Maiello C,Trotta MC,Sardu C,Panarese I,Ferraraccio F,Capuano A,Barbieri M,Balestrieri ML,Napoli C,Paolisso G
Sat Oct 01 00:00:00 UTC 2022
Sodium-glucose cotransporter-2 (SGLT2) expression in diabetic and non-diabetic failing human cardiomyocytes.
Pharmacological research
Marfella R,Scisciola L,D'Onofrio N,Maiello C,Trotta MC,Sardu C,Panarese I,Ferraraccio F,Capuano A,Barbieri M,Balestrieri ML,Napoli C,Paolisso G
Sat Oct 01 00:00:00 UTC 2022
Sodium-glucose cotransporter-2 (SGLT2) expression in diabetic and non-diabetic failing human cardiomyocytes.
Pharmacological research
Marfella R,Scisciola L,D'Onofrio N,Maiello C,Trotta MC,Sardu C,Panarese I,Ferraraccio F,Capuano A,Barbieri M,Balestrieri ML,Napoli C,Paolisso G
Sat Oct 01 00:00:00 UTC 2022
A novel FBW7/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression.
Journal of experimental & clinical cancer research : CR
Liu W,Ren D,Xiong W,Jin X,Zhu L
Wed Jan 26 00:00:00 UTC 2022
A novel FBW7/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression.
Journal of experimental & clinical cancer research : CR
Liu W,Ren D,Xiong W,Jin X,Zhu L
Wed Jan 26 00:00:00 UTC 2022
Dapagliflozin alleviates advanced glycation end product induced podocyte injury through AMPK/mTOR mediated autophagy pathway.
Cellular signalling
Yang L,Liang B,Li J,Zhang X,Chen H,Sun J,Zhang Z
Tue Feb 01 00:00:00 UTC 2022
Renal denervation ameliorates cardiac metabolic remodeling in diabetic cardiomyopathy rats by suppressing renal SGLT2 expression.
Laboratory investigation; a journal of technical methods and pathology
Huo JY,Jiang WY,Zhang SG,Lyu YT,Geng J,Chen M,Chen YY,Jiang ZX,Shan QJ
Fri Apr 01 00:00:00 UTC 2022
Renal oncometabolite L-2-hydroxyglutarate imposes a block in kidney tubulogenesis: Evidence for an epigenetic basis for the L-2HG-induced impairment of differentiation.
Frontiers in endocrinology
Taub M,Mahmoudzadeh NH,Tennessen JM,Sudarshan S
Fri Sep 23 00:00:00 UTC 2022
SGLT2 inhibitor, canagliflozin, ameliorates cardiac inflammation in experimental autoimmune myocarditis.
International immunopharmacology
Long Q,Li L,Yang H,Lu Y,Yang H,Zhu Y,Tang Y,Liu C,Yuan J
Thu Sep 01 00:00:00 UTC 2022
Hepatic expression of sodium-glucose cotransporter 2 (SGLT2) in patients with chronic liver disease.
Medical molecular morphology
Nakano D,Akiba J,Tsutsumi T,Kawaguchi M,Yoshida T,Koga H,Kawaguchi T
Thu Dec 01 00:00:00 UTC 2022
Hepatic expression of sodium-glucose cotransporter 2 (SGLT2) in patients with chronic liver disease.
Medical molecular morphology
Nakano D,Akiba J,Tsutsumi T,Kawaguchi M,Yoshida T,Koga H,Kawaguchi T
Thu Dec 01 00:00:00 UTC 2022
SGLT1/2 as the potential biomarkers of renal damage under Apoe-/- and chronic stress via the BP neural network model and support vector machine.
Frontiers in cardiovascular medicine
Hu GF,Wang X,Meng LB,Li JY,Xu HX,Wu DS,Shan MJ,Chen YH,Xu JP,Gong T,Chen Z,Li YJ,Liu DP
Tue Aug 30 00:00:00 UTC 2022
SGLT1/2 as the potential biomarkers of renal damage under Apoe-/- and chronic stress via the BP neural network model and support vector machine.
Frontiers in cardiovascular medicine
Hu GF,Wang X,Meng LB,Li JY,Xu HX,Wu DS,Shan MJ,Chen YH,Xu JP,Gong T,Chen Z,Li YJ,Liu DP
Tue Aug 30 00:00:00 UTC 2022
High-Salt Attenuates the Efficacy of Dapagliflozin in Tubular Protection by Impairing Fatty Acid Metabolism in Diabetic Kidney Disease.
Frontiers in pharmacology
Zou M,Chen Y,Zheng Z,Sheng S,Jia Y,Wang X,Ren S,Yang Y,Li X,Dong W,Guan M,Zhang Q,Xue Y
Fri Jan 07 00:00:00 UTC 2022
SGLT2 promotes pancreatic cancer progression by activating the Hippo signaling pathway via the hnRNPK-YAP1 axis.
Cancer letters
Ren D,Sun Y,Zhang D,Li D,Liu Z,Jin X,Wu H
Thu Oct 28 00:00:00 UTC 2021
Dapagliflozin reverses the imbalance of T helper 17 and T regulatory cells by inhibiting SGK1 in a mouse model of diabetic kidney disease.
FEBS open bio
Wang D,Zhang Z,Si Z,Yang Y,Li S,Xue Y
Sat May 01 00:00:00 UTC 2021
Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of sodium-glucose co-transporter2 inhibitor treatment.
Molecular metabolism
D'Onofrio N,Sardu C,Trotta MC,Scisciola L,Turriziani F,Ferraraccio F,Panarese I,Petrella L,Fanelli M,Modugno P,Massetti M,Marfella LV,Sasso FC,Rizzo MR,Barbieri M,Furbatto F,Minicucci F,Mauro C,Federici M,Balestrieri ML,Paolisso G,Marfella R
Wed Dec 01 00:00:00 UTC 2021
Redefining the Role of ADAM17 in Renal Proximal Tubular Cells and Its Implications in an Obese Mouse Model of Pre-Diabetes.
International journal of molecular sciences
Palau V,Villanueva S,Jarrín J,Benito D,Márquez E,Rodríguez E,Soler MJ,Oliveras A,Gimeno J,Sans L,Crespo M,Pascual J,Barrios C,Riera M
Fri Dec 03 00:00:00 UTC 2021
Empagliflozin Protects Against Proximal Renal Tubular Cell Injury Induced by High Glucose via Regulation of Hypoxia-Inducible Factor 1-Alpha.
Diabetes, metabolic syndrome and obesity : targets and therapy
Ndibalema AR,Kabuye D,Wen S,Li L,Li X,Fan Q
Fri Apr 15 00:00:00 UTC 2022
Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK/mTOR pathway.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Zhou J,Zhu J,Yu SJ,Ma HL,Chen J,Ding XF,Chen G,Liang Y,Zhang Q
Tue Dec 01 00:00:00 UTC 2020
Empagliflozin Alleviates Hepatic Steatosis by Activating the AMPK-TET2-Autophagy Pathway in vivo and in vitro.
Frontiers in pharmacology
Li T,Fang T,Xu L,Liu X,Li X,Xue M,Yu X,Sun B,Chen L
Wed Feb 10 00:00:00 UTC 2021
Sodium-glucose cotransporter 2 inhibition attenuates protein overload in renal proximal tubule via suppression of megalin O-GlcNacylation in progressive diabetic nephropathy.
Metabolism: clinical and experimental
Otomo H,Nara M,Kato S,Shimizu T,Suganuma Y,Sato T,Morii T,Yamada Y,Fujita H
Tue Dec 01 00:00:00 UTC 2020
Effects of canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells: Multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT).
PloS one
Nakano D,Kawaguchi T,Iwamoto H,Hayakawa M,Koga H,Torimura T
Thu Jul 23 00:00:00 UTC 2020
Effects of canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells: Multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT).
PloS one
Nakano D,Kawaguchi T,Iwamoto H,Hayakawa M,Koga H,Torimura T
Thu Jul 23 00:00:00 UTC 2020
Suppressive effects of the sodium‑glucose cotransporter 2 inhibitor tofogliflozin on colorectal tumorigenesis in diabetic and obese mice.
Oncology reports
Kato J,Shirakami Y,Ohnishi M,Mizutani T,Kubota M,Sakai H,Ibuka T,Tanaka T,Shimizu M
Sun Dec 01 00:00:00 UTC 2019
High Glucose Triggers Nucleotide Imbalance through O-GlcNAcylation of Key Enzymes and Induces KRAS Mutation in Pancreatic Cells.
Cell metabolism
Hu CM,Tien SC,Hsieh PK,Jeng YM,Chang MC,Chang YT,Chen YJ,Chen YJ,Lee EYP,Lee WH
Tue Jun 04 00:00:00 UTC 2019
